Co-Authors
This is a "connection" page, showing publications co-authored by WILLIAM F SYMMANS and DANIEL J BOOSER.
Connection Strength
0.447
-
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010 Sep 20; 28(27):4111-9.
Score: 0.093
-
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 2007 Mar; 8(3):203-11.
Score: 0.073
-
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15.
Score: 0.057
-
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat. 2012 Jul; 134(1):333-43.
Score: 0.026
-
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012 Mar 01; 30(7):729-34.
Score: 0.026
-
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81.
Score: 0.025
-
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011 Feb 02; 103(3):264-72.
Score: 0.024
-
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010; 12(1):R5.
Score: 0.022
-
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7909-16.
Score: 0.021
-
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44.
Score: 0.018
-
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005 Aug 15; 104(4):682-91.
Score: 0.016
-
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 01; 23(25):5983-92.
Score: 0.016
-
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93.
Score: 0.015
-
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 15; 21(18):3454-61.
Score: 0.014